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Key Points: 
 Large-scale, randomized trials to evaluate efficacy of positive airway pressure (PAP) for 
improving patient-reported outcomes and clinical endpoints associated with obstructive 
sleep apnea (OSA) including cardiovascular and metabolic disease have been largely 
negative.  
 Several design-related criticisms have plagued the large-scale PAP trials with a common 
focus on PAP non-adherence among trial participants.  
 Advancing large-scale PAP trial methods to optimize PAP adherence is crucial if the field 
is to be successful in generating valid knowledge of the causal effect of OSA on 
comorbid outcomes.  
 “Best trial practices” that focus on optimizing PAP adherence in large-scale trials are 
needed.  
Synopsis: 
Large-scale randomized trials of positive airway pressure (PAP) efficacy have been largely 
negative yet PAP adherence was notably sub-optimal across the trials. To address this 
limitation, evidence-based PAP adherence protocols embedded within the larger trial protocol 
are recommended. The complexity of such protocols will be dependent on adequacy of 
resources, including funding and inclusion of behavioral scientist experts on the scientific team, 
and trial-specific considerations (e.g., target population) and methods. Recommendations for 
optimizing PAP adherence in large-scale trials are set forth that address rigor and 
reproducibility. 
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Where to Next for Optimizing Adherence in Large-scale Trials of PAP? 
 
Introduction 
 Clinical trials are defined as experiments in humans designed to evaluate the effects of 
specific treatment(s), or exposure condition(s), by reducing random error and bias.5  Effects or 
outcomes evaluated in clinical trials commonly include safety, dosing, efficacy and 
effectiveness.  Phase III trials that evaluate efficacy and/or effectiveness of a treatment 
compared to a standard, alternative or placebo are often designed as large-scale to ensure 
adequate statistical power and potentiate generalizability to the defined target population.5  For 
the purpose of this paper, large-scale trial characteristics include the following: 1) multi-site; 2) 
total sample size greater than 300 participants; and 3) a primary outcome evaluation period 
greater than or equal to three months.   
 In the field of sleep medicine, large-scale trials that meet the above criteria and 
examined the effects of positive airway pressure (PAP) are relatively recent to the literature.  
Driven in part by prior large epidemiological or observational studies of obstructive sleep apnea 
(OSA) and associated comorbidities,6-10 these large-scale trials1-3,11-13 examined the effects of 
PAP on comorbid outcomes, OSA outcomes and/or preventative effects for associated 
comorbidities such as cardiovascular, metabolic and neurological outcomes.  Whereas such 
trials would expectedly provide the field with confirmatory evidence and advance the cycle of 
research for translation to practice, there have instead been questions raised about the validity 
of the results due to design and methodological concerns.  PAP adherence has consistently 
been an area of concern for many of these trials, expressed clearly in noteworthy editorials that 
have accompanied, or followed, the publication of the large-scale trials of PAP.14-19  This review 
will use the recent large-scale trial experience to (1) identify opportunities for increasing rigor, 
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reproducibility and transparency of forthcoming and future large-scale, prospective trials of PAP 
effects and (2) set forth “best trial practices” that directly address PAP adherence while also 
considering key methodologies and opportunities relative to implementing health behavior 
strategies embedded within a larger trial design.   
Large-scale Clinical Trials of PAP 
 In a systematic database search of PubMed Plus, Scopus and ClinicalTrials.gov that 
employed a keyword search strategy (OSA, continuous positive airway pressure [CPAP], 
randomized controlled trial [RCT] or trial) with delimiters for adult and publication date from 2000 
to current [February 1, 2020], six trials were identified that additionally met criteria for: (1) the 
large-scale definition employed herein, (2) an objective measurement of PAP use/adherence, 
and (3) reported PAP use in the primary results publication (Table 1).  The majority of excluded 
trials did not meet the review-specific large-scale definition for sample size or outcome interval 
duration or failed to fully report PAP use with the primary results.  Across the included trials, 
PAP use ranged from 2.3 – 5.0 hours/night (mean or median). In trials reporting a PAP 
adherence criterion, approximately half of the samples met the commonly reported PAP 
adherence criterion of ≥ 4 hours/night.  The trial samples were characteristically similar with the 
exception of two trials that had target populations without excessive daytime sleepiness12 (i.e., 
by Epworth Sleepiness Score criterion) and/or minimally-symptomatic individuals with OSA2 
(i.e., absence of other patient-reported OSA symptoms).  Studied samples were predominantly 
male, middle-aged, obese adults with moderate to severe OSA.  All trials set forth a primary 
objective to evaluate PAP effects, absent explicit use of the term, “efficacy.” PAP was compared 
to at least one other exposure condition, to evaluate the primary outcome assessed at or after 
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three months of exposure.  Primary outcome results were largely negative, or supportive of the 
null hypothesis, across the trials. 
 Evaluation of efficacy, or the true biological effect of a treatment,5 necessitates exposure 
to the test and comparator condition(s) to permit the exploration of patient-reported outcomes 
and/or clinical endpoints that are the efficacy outcome(s).  Efficacy is evaluated in the trial 
setting wherein internal validity is prioritized, notably to the detriment of external validity, or the 
generalizability to practice.20  Evaluation of effectiveness, or outcomes of the test and 
comparator relative to usual, real-world conditions, may similarly examine biomedical end-points 
but, by design, prioritize external validity for addressing practice and policy priorities.20  
Effectiveness is the “effect of a treatment when widely used in practice.”5   
 The identified large-scale trials of PAP all report a primary objective to evaluate the 
effect of PAP on a primary endpoint and report designs and analytical methods (e.g., intention-
to-treat) consistent with efficacy evaluation.  Yet, when the published protocols and primary 
results with supporting documents (i.e., supplement, appendix) are carefully scrutinized, the 
methodologies and procedures specific to the PAP exposure condition are likened to protocol 
methods consistent with effectiveness evaluation.  Such methods are reflective of standard 
practice, or usual care.  For example, a trial that reports providing participants with contact 
information for device troubleshooting after providing standard OSA and PAP patient education, 
including device set-up and mask fitting for longer large-scale trials, subsumes participants will 
acknowledge and recognize specific barriers to PAP use and then initiate contact.  This 
example is more consistent with standard practice and is thereby better aligned with 
effectiveness evaluation wherein the “effect of treatment in practice” is the trial objective.  While 
effectiveness trials are imperative to the field, efficacy evaluations cannot, and should not be 
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forgone, as knowledge of PAP efficacy is central to defining treatment standards of OSA by 
varied outcomes, including comorbid outcomes of physiological and clinical importance.  
Furthermore, efficacy evaluations from randomized trials are viewed as among the strongest 
evidence towards answering questions of causality (i.e., does OSA cause comorbid outcomes 
of clinical importance). 
Rigor and Reproducibility of PAP Adherence Protocols in Large-scale Trials of PAP 
 Critical insights from the large-scale PAP trials published to date provide the field with an 
opportunity to consider how efficacy trials will need to explicitly address PAP adherence within 
the larger trial protocol to better meet the requirements for rigor and reproducibility as defined by 
National Institutes of Health (NIH)21 and similarly emphasized by other federal agencies.22,23  
Trials included herein were designed by teams of interdisciplinary scientific investigators with 
relevant expertise (Table 2) and supported by at least one federal or regional agency.  
Resources for trial conduct and oversight (internal and external) were clearly explicated in half 
of the trial reports,1,3,13 suggesting careful attention to trial operations that is consistent with the 
safe, ethical and rigorous conduct of efficacy trials.   
 There are noteworthy gaps, specific to PAP exposure and PAP adherence protocols, 
across the included trials that can be leveraged for optimizing PAP adherence in the next 
generation of large-scale trials of PAP efficacy.  For example, an absence of evidence-based 
behavioral approaches to support PAP use was observed.  Some of these gaps are likely 
attributed to the state of PAP adherence science at the time of planning and conducting the 
trials.  Other gaps may be relative to a myriad of contributors including the absence of clear 
guidance and/or expectancies for reporting efficacy trial PAP adherence protocols at the time of 
grant submission and subsequent publication(s) related to the trial.    
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 Methods specific to PAP adherence were abstracted from all available published 
sources for each trial, including primary results publications, design and methodology 
publications, publicly-accessible protocols, trial registry data, grant databases (e.g., RePORTER 
for NIH-funded studies), and secondary results publications if available (Table 3; see online 
supplement for detailed methods).  Corresponding authors identified on the primary results 
publication were also contacted when published or publicly-available sources lacked information 
or data specific to PAP adherence methods reported in Table 3.  Sorting the reported PAP 
adherence methods by study period revealed important similarities and differences between 
these trials for PAP adherence protocols (Box 1; Box 2).   
PAP Adherence Criterion   
 All trials but one13 identified a PAP adherence criterion, most often defined in the 
analysis or results section of the respective published papers.  This criterion was consistently 
reported as ≥ 4 hours/night of average PAP use without explicit rationale.  There were no 
methodological details provided for the specified protocol periods during which the criterion was 
to have been met; and, if the criterion was not met in any specific interval, there were no reports 
of specific PAP adherence protocols that were employed other than “study contact was 
initiated.”  All trials reported designated visits at which time PAP adherence was electronically 
retrieved or downloaded.  Two trials1,3 reported using a PAP adherence criterion to guide study 
contact with participants; these interactions were either by phone and/or at an additional 
research visit to address low PAP adherence.  No protocol-based, pre-specified actions were 
reported for the low PAP adherence interactions.   
Trial PAP Exposure ≤ 4 Months & Adherence Protocols   
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 All trials reported that mask-fitting, equipment review and education were provided by 
trained or experienced study personnel.  Only one trial reported the educational approach 
employed with participants, using three education modalities to deliver the information.13  No 
trials reported specific educational content that was provided to the trial participants.  Mask 
and/or humidification choice was prioritized relative to adherence in one trial2 while others 
specified that humidification and “best-fit” mask were provided.3,13  In some trials,1-3,11 trouble-
shooting, “support for adapting to PAP” and “advice” were reported as protocol activities in the 
first several weeks to four months. 
Trial PAP Exposure > 4 Months & Adherence Protocols   
 All included trials except one13 assessed a primary endpoint with PAP exposure greater 
than four months.  The SAVE trial3 was the only trial that reported using a specific PAP 
adherence protocol extending beyond four months. This trial, with a large number of sites 
extending around the globe, was also unique in that a centralized study structure, Sleep 
Laboratory Core, was charged with monitoring PAP use across sites and provided centralized 
expert advice to sites when PAP adherence was below the study-defined criterion. The SAVE 
trial also employed PAP use, leak and residual apnea-hypopnea index (AHI) criteria from PAP 
initiation to study end with PAP remote monitoring.3 
 When the trials are considered collectively, PAP adherence protocols are generally 
under-reported, which limits reproducibility and impacts evaluation of the rigor for the reported 
work. This weakness limits the potential for other investigators to address the challenge of 
optimizing PAP adherence in subsequent large-scale PAP trials.  The included trials report 
methods that are seemingly consistent with earlier published clinical practice guidelines24 and 
with what the field considered “standard practice” at the time of these trials.  The PAP 
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adherence achieved in the included trials is therefore not unexpected given 1) the modest trial 
PAP adherence protocols and 2) the observation that across PAP clinical trials and clinical trial 
follow-up observational studies, the weighted average of PAP use was 4.46 hours/night and 
average non-adherence rate was 36.3%.25  These observed metrics of PAP adherence are 
consistent with other reviews that have addressed summary PAP adherence across studies.26,27 
The obvious concern is that this level of PAP adherence is sub-optimal for a rigorous 
assessment of efficacy.   
 The overwhelmingly negative results across the large-scale trials coupled with the 
minimalist approaches to PAP adherence within the conduct of the efficacy trials provide the 
evidence and the necessary motivation for future large-scale trials to carefully design and report 
PAP adherence protocols in great detail.  These protocols will need to use the current PAP 
adherence evidence to potentiate higher PAP adherence across study participants.  Such 
adherence protocols should be embedded within the larger trial protocol to ensure 
reproducibility and strengthen rigor relative to PAP adherence.  This approach will best position 
large-scale efficacy trials to test PAP by providing results that are unbiased relative to 
adherence.        
State of the Science: PAP Adherence 
     Since the earliest large-scale trial1 was conducted, PAP adherence intervention studies 
have been increasingly represented in the literature. The body of evidence has recently been 
systematically examined, resulting in a meta-analysis4 that supports the current American 
Academy of Sleep Medicine’s clinical practice guideline for the PAP treatment of adults with 
OSA.28  The meta-analyses addressed PICO (Population, Intervention, Comparison, Outcome) 
questions of which eight of the 11 questions included PAP adherence as an outcome (Box 3).  
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The cumulative set of reviewed evidence (n=1,512) was reduced to a final set of 184 studies 
that addressed one or more of the PICO questions;4 for each PICO question, a sub-set of 
studies were eligible for meta-analysis.  With a pre-specified clinical threshold of significance for 
the PAP adherence outcome set at 0.5 hours/night or 10% patient use > 4 hours/night, the 
results of the meta-analysis support the accompanying practice guidelines.28  Explicit PAP 
adherence interventions addressed by the meta-analyses and subsequent practice guidelines 
include educational, behavioral and tele-monitoring recommendations; on average, these 
interventions, individually, result in an estimated PAP use effect of 1.0 hour/night (Figure 1).  
The available cumulative evidence provides guidance for designing evidence-based PAP 
adherence protocols for future large-scale efficacy trials.   
Advancing PAP Adherence Protocols in Large-scale PAP Trials 
 Recommendations for using evidence-based PAP adherence protocols in large-scale 
trials include 1) tele-monitoring, 2) behavioral approaches and 3) education.  In addition, other 
methodologies can be leveraged to improve PAP adherence, including 1) using a PAP run-in 
period and 2) considering sampling criteria specific to PAP adherence.  Due to the well-
recognized heterogeneity in PAP adherence behavior and factors that are associated with this 
behavior,26,27 a multi-component PAP adherence protocol is best-suited for large-scale trials.  
Investigative teams will need to carefully balance the complexity and required expertise for 
these protocols with feasibility and resource considerations.  This is particularly poignant as the 
large-scale PAP trials to date have been summarily under-funded (Box 4).  
Tele-monitoring 
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 With the advancement of PAP technology by industry, the field is well-positioned to 
objectively measure PAP adherence and capitalize on near real-time treatment usage and 
effectiveness data.  Future large-scale trials will leverage this technology in PAP adherence 
protocols to guide PAP interventions.  Study-defined criteria for PAP adherence by study 
intervals (e.g., first week, first month) and by near real-time intervals (e.g., within consecutive 
days) can be established.  This approach, if adjoined with a response-to-PAP use plan (e.g., 
tele-coaching), supports early intervention for PAP non-adherence29 and conservation of 
resources within the trial.  This is important as evidence from observational studies has 
consistently identified that early PAP use is a predictor of long-term PAP use;30,31 similarly, 
analyses of PAP trial data has demonstrated the same.32,33  The recommendation for employing 
a tele-monitoring and response-to-PAP use protocol within large-scale trials also potentiates 
engagement which is a relevant consideration for improving or changing health behavior(s).34-37  
Employing both participant- and trial-facing applications and/or web-based portals that may be 
industry-supported, or study-specific, are strategies that support PAP use during the active 
engagement period;37-42 importantly, PAP use may attenuate after engagement concludes.38  
When using industry-supported applications and tele-monitoring platforms, industry partners 
bring knowledge on how these digital solutions work and experience from other trials to support 
streamlined data acquisition and integration.     
 When designing the PAP adherence tele-monitoring protocol, the following factors 
should be carefully considered: 1) pre-defined usage thresholds in industry-supported tele-
monitoring solutions and the alignment of these thresholds with trial-defined usage criterion; 2) 
centralized and/or site level tele-monitoring and response-to-PAP use responsibilities and 
protocols; 3) resources necessary to maintain tele-monitoring protocols; 4) participant burden, 
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including ethical considerations for informed consent language addressing the schedule of 
interactions (i.e., intensity); and 5) innovative approaches that can be employed to automate 
tele-monitoring response actions by the trial team, whether at a centralized or site-level, with 
specific intention to deliver response actions by communication methods that are defined by 
participant preference (e.g., video visits, text messaging, online chat access as opposed to 
telephone calls and face-to-face visits).   
Behavioral Approaches 
 Several behavioral approaches for PAP adherence can be considered for large-scale 
trials.  The field of behavioral sleep medicine has significantly grown over the past 10 years as 
has the inter-disciplinary field of experts in behavioral sciences who can provide required 
expertise for planning and delivering behavioral approaches for PAP adherence in large-scale 
trials.  Determining which behavioral approach(s) to embed in a large-scale PAP trial will be 
guided by the evidence at the time of planning the trial, expertise of the trial team, schedule of 
research visits and/or interactions, and the target population/sample of the trial.   
 Behavioral interventions tested with positive effects for PAP adherence to date have 
been delivered at the outset of PAP treatment (e.g., at PAP initiation) to PAP-naïve adults with 
OSA.43-47  Included in this review, one large-scale trial indicated by corresponding author 
communication that motivational or cognitive strategies were employed to encourage PAP 
adherence without further details; this protocol activity was not reported in the study 
publications.11,48  Based on the publications and corresponding author communications, it is 
unknown if other trials included in this review also used behavioral approaches for PAP 
adherence.  It is recommended that these behavioral protocol activities be fully-reported by 
future large-scale trials.  Reporting guidance that can be used include the SPIRIT guidelines49 
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(Standard Protocol Items: Recommendations for Interventional Trials) and TIDier guidelines50 
(Template Intervention Description and Replication checklist and guide; both available at 
https://www.equator-network.org/.  Other important considerations for embedding behavioral 
approaches include: 1) timing and format of delivery; 2) centralized and/or site-level oversight, 
training and management of behavioral approaches; 3) resources required to maintain delivery 
of behavioral approaches during trial execution, including fidelity assessments; 4) participant 
burden, including informed consent language addressing the schedule of interactions (i.e., 
intensity); and 5) including a behavioral scientist as a team member with expertise specific to 
the phenomenon of PAP adherence, or health behavior. 
Education 
 Disease and treatment education is a practice norm at diagnosis and treatment initiation 
in OSA, consistently set forth by consensus24 or strong recommendation.28  Though the effect of 
education on PAP adherence is notably modest,4 it is an essential component of behavior 
change.51  Education about OSA and PAP was a consistent protocol activity in the trial setting 
based on our review of large-scale PAP trials.  Considering the diverse (e.g., geographic, 
literacy, culture) nature of participants in PAP randomized trials, and to minimize the risk of 
excluding sub-groups with different or special needs (e.g., language, visual impairment, low 
health and general literacy), the content and delivery mode(s) of education materials should be 
designed with attention to these needs.  Recent evidence suggests commonly used sleep 
education materials that are widely available from American Thoracic Society and American 
Academy of Sleep Medicine have high health literacy demands, requiring high school level or 
higher education.52  Understandability and clear communication indices of the materials were 
also scored low.52  The Centers for Disease Control and Prevention and Agency for Healthcare 
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Research and Quality provide explicit guides and information for designing and delivering health 
information to varied audiences;53,54 trial teams are urged to use such resources when designing 
educational materials (see also: http://centerforhealthguidance.org/health-literacy-principles-
checklist.pdf ).  If selecting publicly- or commercially-available materials for trial use, evaluation 
of the materials with more than readability procedures is important (e.g., Flesch-Kincaid tests).  
Other recommendations include 1) consulting with or having a team member with education 
expertise specific to the delivery of health information; 2) pilot testing trial education materials 
with a representative group of patients and revising materials as indicated; and 3) exploring 
multi-modal delivery of educational materials to trial participants at varied study intervals so as 
to “off-load” demands at the outset of PAP initiation. 
Incentives 
 The behavioral economics framework assumes that people make decisions with error 
and “nudges” are needed to increase the likelihood of good decisions, or decisions that are in a 
person’s best self-interest.55,56  Nudges can take many forms including, but not limited to, 
incentives and rewards which may be financial in structure.  Using incentives and rewards as an 
intervention approach for health behavior is an emerging area of study across the literature; yet, 
a relatively small body of evidence exists for PAP adherence in patients and no studies, to our 
knowledge, report on incentives directed to research sites/teams for PAP behavioral 
intervention delivery.  Use of incentives in large-scale PAP trials for participants and/or sites and 
staff must be considered with caution as the effects, ethics and methodologies are not well-
understood.  As has been recently acknowledged,57 financial incentives do not always work.  
There are a myriad of details that must be understood before embedding such incentives in a 
study; “the devil is in the detail, because the magnitude of effects differs substantially based on 
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the nature of the behavior, the size of the incentive, the population involved, the social context 
and the design [of the incentive].”58   
 If, however, incentives and rewards are conceptualized as non-financial, the ethical 
concern for coercive effects and distributive inequity are lessened.58  Such incentives and 
rewards, for example, might include de-identified “performance” metrics with comparative 
ratings and messages (e.g., “Kudos Reports”), goal tracking worksheets/visualizations to 
explicate incremental progress with digital badges and personal rewards-to-self that are based 
on self-appraisal metrics.  These are but a few examples derived from both behavioral 
economics theory and the existing PAP adherence evidence that address goal-directed 
behavior change, engagement and motivation.  Though the state-of-the-science for financial 
incentives for PAP adherence is yet under-developed, incentives are likely to be a consideration 
for future large-scale trials with scientific advancement in behavioral economics for sleep and 
PAP adherence.59        
Run-In Methods 
 Randomized trials may employ a run-in, or a pre-randomization exposure period to the 
active or placebo condition(s), in order to exclude non-adherers, placebo responders, active 
condition non-responders or active condition intolerance.60  Run-in methods are not uncommon 
in industry and/or pharmacologic trials, but are less common in PAP trials,46 including large-
scale trials.3  Employing run-in periods is not without controversy however, as external validity is 
compromised when a run-in period is used.61  This is because the representativeness of the trial 
sample will necessarily differ from the clinical target population.  Yet, when efficacy is the 
primary aim of the trial, internal validity is prioritized unlike in effectiveness trials.  Another 
concern to be carefully considered in implementing a run-in period is the impact that a positive 
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PAP experience, and positive treatment effects, may have on cross-over rates, wherein subjects 
having done well with PAP and then randomized to the comparator condition may decide to 
obtain PAP therapy outside the trial.  Similarly, in trials where active PAP is compared to 
placebo, or sham PAP, and sham PAP or a modified PAP profile (e.g., mask/headgear only) is 
used during the run-in, subsequent use of PAP, or adherence, may be affected by the run-in 
experience.  For example, cognitive perceptions of PAP are different (e.g., lower outcome 
expectancies) with sham versus active PAP.62  In addition, when a placebo is the trial 
comparator such as with sham PAP, the risk of un-blinding must be carefully navigated when 
using run-in methods.     
 There are important considerations when planning a run-in period for a large scale PAP 
trial which include: 1) monitoring run-in data to support fully reporting the number of run-in 
exposures conducted, failed run-in rate, and run-in participants’ (failed and completed) 
characteristics compared to the trial sample; 2) determining and reporting run-in PAP adherence 
criteria which should be consistent with the post-randomization PAP adherence criteria if the 
run-in is designed to reduce the overall risk of bias introduced by non-adherence; and 3) 
determining if failed run-in will be repeated based on pre-specified criteria.  Most trials that have 
reported run-in periods have not adequately described the run-in protocol nor run-in results to 
address concerns about sample representativeness.63  As of the writing of this review, there are 
no published guidelines for run-in period reporting; until such are available, large-scale trials that 
employ a run-in period will need to carefully consider the implications of the run-in methods on 
the overall trial results.  Statistical expertise and trial methodologists are recommended to best 
guide these considerations. 
Sampling Criteria Methods 
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 A robust evidence set exists that addresses influential factors on PAP adherence.26,27,64  
The evidence suggests that these factors may be measurable at baseline in the efficacy trial 
setting and employed as sampling criteria to potentiate PAP adherence.  When considering this 
approach it is important to reflect on how the selected factors may impact on enrollment rates 
and trial sample characteristics.  The measurement, or screening, for such factors must also be 
feasible using validated instruments.  Consideration must be given to the burden of 
measurement, ethical decision-making for sampling criteria and timing of measuring such 
factors.  If predictive factors of PAP adherence are employed as sampling criteria to potentiate 
PAP use in the efficacy trial setting, this will necessarily have implications on generalizability.  
For this reason, investigators might examine site-level target population characteristics and 
determine the effect of imposing the sampling criteria specific to PAP adherence on sample 
accrual and characteristics at the trial design phase.  This approach may best reduce sampling 
feasibility concerns while also providing data-based insights for statements of generalizability.       
              Future large-scale trial teams will need to remain abreast of emerging evidence for 
PAP adherence interventions and employ innovative and tested approaches to best optimize 
PAP adherence in the setting of an efficacy trial.  No single approach to PAP adherence 
interventions within any trial is recommended but rather, embedding evidence-based 
interventions that are aligned with: 
 trial team expertise (see next section, Trial Team Composition),  
 the a priori threshold for PAP adherence for the end-point,   
 the estimated PAP use in the target population based on prior published observational 
studies or pilot trials, and 
 trial resources.  
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Both investigators and funding agencies will necessarily embrace increasingly complex trial 
designs that necessitate thoughtful trial planning periods and nuanced trial management 
plans/processes and structures for successfully conducting these trials. 
What Does the Future of Large-scale Trials of PAP Look Like? 
 Designing and conducting the next generation of large-scale PAP trials is a critical 
consideration for the field based on recent trial experiences.  Explicit opportunities that are 
germane to addressing the rigor and reproducibility aspects of large-scale prospective PAP 
trials and thereby reducing concerns for internal validity specific to PAP adherence include (1) 
trial team composition, (2) operational structure, (3) protocol-within-protocol design, (4) protocol 
execution, and (5) trial reporting.  By setting forth these recommendations for large-scale PAP 
trials, the stage is set for substantive dialogue among investigators, funding agencies and trial 
partners (e.g., industry, technology/innovation) in order that “best trial practices” for large-scale 
PAP adherence efficacy trials are commonplace. 
Trial Team Composition   
 Adherence to a new health behavior, such as in the trial setting with assignment to PAP 
among treatment-naïve adults with OSA, is challenging for both participants and the trial team.  
Trial investigators and site staff may have substantial clinical and/or practical experience with 
introducing PAP and managing PAP adherence but this is not necessarily transferrable to a trial 
setting.  For example, unlike research participants who should have equipoise about receiving 
PAP therapy, patients presenting for clinical care, by virtue of seeking care, are motivated to 
initiate treatment.  Also unlike the clinical setting, time-to-adherence is of high importance in 
large-scale PAP trials due to pre-defined outcome assessments and study resource-constraints.  
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Active adherence interventions that consist of more than device/equipment trouble-shooting and 
advice may not be well-developed skills among staff and investigators with primarily practice-
based experience who manage a wide range of sleep disorders and treatments.   
 Behavioral science is a distinct field.  While investigators of these large-scale trials may 
have practical health behavior experience, this does not necessarily equate to depth and 
breadth of knowledge and application of behavioral health interventions that are scientifically-
derived; nor does such practical experience equate to measurable performance outcomes as is 
necessary in these trials.  Trial team composition must therefore be carefully considered at the 
earliest planning stages of the trial.  At the investigator level, a behavioral scientist with 
expertise in PAP adherence will ideally be included and lead the protocol for PAP adherence.  
This approach will potentiate a scientifically-sound protocol specific to PAP adherence and an 
investigator with committed time and focus for this methodological and implementation work.   
 Another key consideration for team composition is successfully recruiting and retaining 
site-level staff members that may, or may not, have relevant experience but who are amenable 
to learning and consistently applying behavioral protocol activities as prescribed.  Retention of 
staff ensures consistency of contact between the trial site and participants.  This is similarly 
applicable if a centralized structure, or core, is designated for PAP adherence in the trial.  Staff 
with strong communication skills, including skills for developing rapport and active listening, are 
imperative to the success of delivering health behavior interventions such as those with positive 
effects for PAP adherence (see Figure 1).  These team composition recommendations are 
directly supportive of behavioral and implementation science approaches that address 
partnership, engagement and collaboration as the cornerstone of health behavior change,34,65,66 
including recent work in the PAP adherence field addressing technology-driven patient 
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engagement,37 a vision for patient-centered approaches to OSA and PAP management67 and 
emphasis on team approaches for PAP adherence.68  
 The introduction of stakeholder advisory boards that may include patients, community 
leaders and/or clinical providers has emerged as a research priority in many countries, including 
the U.S., U.K., Canada and Europe.69  Designing PAP adherence protocols for employ within an 
efficacy trial with patient stakeholders has yet to be reported to our knowledge; in fact, patient 
engagement across published randomized controlled trials has been limited to date.69  However 
this approach may be an innovative opportunity for large-scale PAP trials.  Patient preferences 
for protocol activities, for example communication frequency and mechanism, can be accounted 
for from the outset of the trial with input from patient stakeholders, or advisors.  This may 
potentiate participant acceptability of the PAP adherence methods and protocols70 and thereby, 
trial enrollment and retention.  Resources for researchers considering engagement approaches 
at any study phase, but as suggested here at the trial design level, can be found at Patient 
Centered Outcomes Research Institute website 
(https://www.pcori.org/engagement/engagement-resources/Engagement-Tool-Resource-
Repository).      
Operational Structure  
 From the outset of trial planning, the investigative team should consider the development 
of a PAP Adherence Core, a centralized operating structure specific to PAP adherence.  
Consistent with the more commonly reported trial structure of a Sleep Reading Core or Sleep 
Laboratory Core, the PAP Adherence Core investigators who have scientific and 
implementation expertise in health behavior change and PAP adherence will design protocols 
specific to PAP adherence that are embedded within the larger trial protocol.  Oversight for 
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adherence protocols is a central responsibility of the Core, including training, protocol fidelity 
and quality of protocol implementation.  By centralizing these functions among a dedicated 
Core, the necessary knowledge and skill to support site-based staff and investigators for PAP 
adherence can be efficiently managed.  Increasingly focused intervention approaches to PAP 
adherence that are evidence-based can be designed with an expert core; these approaches can 
be carefully aligned with the larger trial protocol (i.e., protocol-within-protocol, or a nested 
protocol).  In order for this approach to be successful, the PAP Adherence Core investigators 
must be engaged with the trial investigators/team from the earliest point possible in the design 
of the trial and function as active trial team members.  This approach will ensure that all trial 
activities that bear influence on participants’ use of the test condition will be addressed from a 
behavioral perspective from design through results reporting.   
Trial Execution   
 A dedicated PAP Adherence Core will necessarily design and deliver training specific to 
PAP adherence protocols.  As most large-scale trials include a Training or Education 
Committee, the Core will work collaboratively with the larger Committee to ensure all trial-
specific standards and expectations are met with delivery of PAP adherence training.  In the 
setting of large-scale trials that have numerous geographically disperse sites, training 
approaches will need to be increasingly innovative yet effective in the delivery to conserve trial 
resources (Box 5).  Areas of training consideration by the Core will include: training content, 
delivery modes and styles of training content, performance standards relative to training 
sessions and ongoing monitoring performance standards, certification and re-certification of 
staff for all procedures.  Contingency training plans for newly hired staff and for those previously 
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certified staff who demonstrate a need for booster training identified during the protocol fidelity 
monitoring procedure is also recommended.   
 Fidelity monitoring procedures should be designed by the PAP Adherence Core and 
monitoring intervals and procedures established in collaboration with relevant trial entities, most 
likely to include the Data Coordinating Center (DCC).  By establishing partnerships between the 
Core and the DCC which is a cornerstone of efficient data monitoring in large-scale trials, fidelity 
monitoring of PAP adherence intervention protocols and performance metrics for quality 
protocol delivery will be meticulously tracked and communicated to the Core and study 
investigators. Thresholds for fidelity and protocol delivery, established by the Core and trial 
investigators, will subsequently guide remediation, or booster, training decisions, adjustment of 
monitoring intervals, and trial site evaluation and feedback.  Though these thresholds are 
directly aligned with sub-optimal performance, the Core will also ideally recognize and reward 
consistent performance above the threshold and exceptional performance.   
Trial Reporting                             
  Reporting of PAP adherence protocols in large-scale trials should be included with the 
methodology publication and/or with the primary results publication.  Though page limitations 
may be prohibitive of a complete reporting of PAP adherence protocols, supplemental or 
appendix materials can be used to fully report the protocol.  To support both rigor and 
reproducibility guidelines, a minimum description of PAP adherence protocols should include: 
 All intervention approaches employed by protocol period/interval 
 Complete description of all intervention methods 
 PAP adherence criterion and rationale 
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 Measurement methods of PAP adherence employed and measurement intervals 
 Description of training for delivery of intervention(s) 
 Fidelity monitoring plan including performance thresholds at study- and site-level 
 When reporting trial results, PAP adherence should be reported as a summary 
continuous research variable (mean hours/night) at trial end-point and by study interval for trial-
relevant periods (e.g., scheduled recurrent research visits).  Because PAP adherence is usually 
not normally distributed, reporting PAP use by only mean and standard deviation can be 
misleading.  Therefore, PAP adherence criterion for the trial should also be reported as a 
frequency at trial end-point and by study interval at trial-relevant periods.  Any pre-specified per-
protocol analyses based on PAP adherence should also be reported with trial results.  Protocol-
based results that are of importance to report include summary fidelity results at the study-level 
and training completion rates, including booster/remediation training conducted throughout the 
trial period.    
Conclusion 
 Prospective efficacy trials are requisite to setting forth treatment standards and 
guidelines and generate causal effects knowledge.  Though innovative comparative 
methodologies that employ big data and precision health scientific methods are likely to also 
contribute treatment standards and guidelines, prospective efficacy trials of a large-scale nature 
will continue to be necessary.  Recent efficacy trials of PAP therapy have been challenged by 
concerns for validity relative to low PAP use, or non-adherence.  Careful scrutiny of these 
precedents shed light on opportunities to address PAP adherence in forth-coming and 
subsequent trials.  In order that PAP adherence is optimized, evidence-based protocols focused 
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on PAP use should be embedded within the larger trial protocol.  In doing so, investigators will 
need to carefully balance numerous factors relative to feasibility, ethical trial conduct and overall 
study rigor.  Important considerations are highlighted in this review to facilitate dialogue in the 
field for “best trial practices” that are specific to PAP adherence, including reporting guidance at 
the time of funding application, methodology and results/protocol publications.  It is with 
attention to these opportunities that there will be reduced concern for the validity of large-scale 
PAP trial results and these trials will meet expectancies for rigor and reproducibility.      
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Figure 1. Evidence-based PAP Adherence Interventions and their Estimated Improvement for 
PAP Adherence.   
Caption.  Adapted with permission from Patil, et al., 2019.  Estimated effects for PAP adherence 
(i.e., use) are meta-analyses results reported in Patil, et al., 2019.4 
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Table 1. Description of Published Large-scale Trials (n=6) 
 
Notes. APPLES, Apnea Positive Pressure Long-term Efficacy Study; Spanish Cohort Trial; MOSAIC, Multicenter Obstructive Sleep 
Apnea Interventional Cardiovascular trial; HeartBEAT, Heart Biomarker Evaluation in Apnea Treatment; SAVE, Sleep Apnea 
Cardiovascular Endpoints study; ISAACC, Impact of Sleep Apnea syndrome in the evolution of Acute Coronary syndrome.  
Abbreviations- Yr, years; mo, months; h, hours; CPAP, Continuous Positive Airway Pressure; OSA, Obstructive Sleep Apnea; NR, 
Not Reported; HTN, Hypertension; CV, cardiovascular; MACE, Major Adverse Cardiovascular Event; CVD, Cardiovascular Disease; 
ACS, Acute Coronary Syndrome.  
Trial  
(Project 
Years) 
Location (Sites) Primary 
Endpoint 
Follow
-up 
 
Study Sample Intervention (N) Comparator 
(N) 
PAP Use 
Criterion 
Adherence 
  
Primary 
Outcome 
(+ or -) h/night % ≥4 h 
APPLES1 
2003 - 2008 
US (5) 
Neurocognitive 
function 
6-mo OSA patients 
 
CPAP 
(n=556) 
 
Sham-PAP 
(n=542) 
≥4 
 
4.2 
 
56.2% − 
Spanish 
Cohort2 
2004 - 2009 
Spain (14) 
Incident HTN & 
CV events 
3-yr 
OSA patients 
(Non-sleepy) 
 
CPAP 
(n=358) 
 
No treatment 
(n=367) 
≥4 
5.0 
 
64.4% − 
MOSAIC3 
2006 - 2010 
UK/Canada (10) CV risk score 6-mo 
OSA patients 
(Non-sleepy) 
 
CPAP 
(n=195) 
 
Usual care 
(n=196) 
≥4 
2.4 
 
NR 
 
− 
HeartBEAT4 
2010 – 2012 
US (4) 24-hr BP 3-mo 
Cardiology patients 
with OSA 
CPAP (n=106) 
Oxygen (n=106) 
 
Lifestyle 
education 
(n=106) 
NR 
3.5 
 
NR + 
SAVE5 
2008 - 2015 
Australia, China, 
New Zealand, 
India, Spain, US, 
Brazil (89) 
MACE 4-yr 
CVD patients with 
OSA 
CPAP (n=1359) 
Usual care 
(n=1358) 
≥4 
3.3 
 
42% − 
ISAACC6 
2011-2018 
Spain (15) MACE ≥1-yr 
ACS patients with 
OSA 
CPAP (n=633) 
Usual care 
(n=631) 
≥4 
2.8 
 
37.5% − 
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Table 2.  Scientific Trial Team Members by Discipline or Specialty† 
 
 
 
 
 
 
Notes. APPLES, Apnea Positive Pressure Long-term Efficacy Study; Spanish Cohort Trial; MOSAIC, Multicenter Obstructive Sleep Apnea 
Interventional Cardiovascular trial; HeartBEAT, Heart Biomarker Evaluation in Apnea Treatment; SAVE, Sleep Apnea Cardiovascular Endpoints 
study; ISAACC, Impact of Sleep Apnea syndrome in the evolution of Acute Coronary syndrome.  
†Identified by author affiliation(s) in methodology and/or result publication.  
 
 
 
 
 
 
 
 
 
 
Discipline Involved APPLES 
Spanish 
Cohort 
MOSAIC HeartBEAT SAVE ISAACC 
Sleep Medicine + + + + + + 
Respiratory Medicine + + + + + + 
Clinical Trialist and/or Statistics + - + + + + 
Study-Specific Discipline Relative to Biomedical Focus + - - + + + 
Behavioral Science - - + - - - 
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Table 3.  Concentration of Methods Specific to Positive Airway Pressure Adherence by Large-scale Trial Study Period (n=6) 
Trial Name  Screening 
Criteria† 
Or  
Other Pre-
Randomize 
Methods  
Random 
Assignment‡ 
PAP 
Initiation 
Wk 1  Mo 1  > Mo 1  
PAP Exposure 
 
APPLES 
 
+ 
 
+ 
 
+ 
 
++ 
 
+ 
 
++ 
 
Spanish Cohort Trial 
 
− 
 
− 
 
++ 
 
− 
 
− 
 
− 
 
MOSAIC 
 
+ 
 
− 
 
++ 
 
− 
 
+ 
 
+ 
 
HeartBEAT 
 
+ 
 
− 
 
+++ 
 
− 
 
− 
 
− 
 
SAVE 
 
+++ 
 
+ 
 
+++ 
 
++ 
 
+++ 
 
++ 
 
ISAACC 
 
+ 
 
− 
 
+++ 
 
++ 
 
++ 
 
+ 
 
Notes. APPLES, Apnea Positive Pressure Long-term Efficacy Study; Spanish Cohort Trial; MOSAIC, Multicenter Obstructive 
Sleep Apnea Interventional Cardiovascular trial; HeartBEAT, Heart Biomarker Evaluation in Apnea Treatment; SAVE, Sleep 
Apnea Cardiovascular Endpoints study; ISAACC, Impact of Sleep Apnea syndrome in the evolution of Acute Coronary 
syndrome. 
†Inclusion and Exclusion Criteria that are specified for PAP adherence in methodology and/or result publication and/or 
supplemental/appendix materials and/or publicly-availably protocol materials. 
 ‡Reported protocol activities specific to PAP use/initiation/adherence conducted concurrently with randomization.  
(−), zero reported method; (+), 1 reported method; (++), 2 reported methods; (+++), 3+ reported methods. See Online 
Supplement for detailed reported methods. 
  
Abbreviations – PAP, Positive Airway Pressure; Wk, Week(s); Mo, Month(s). 
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Box 1:  Consistent PAP Adherence Methods in Large-scale PAP 
Efficacy Trials (n=6) 
 Exclusion Criteria 
 Prior PAP use 
 PAP Initiation 
 By trained (or experienced) study personnel 
 PAP Use Measurement 
 Objective at varied study intervals 
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Box 2: Exceptional† PAP Adherence Methods in Large-scale PAP Efficacy Trials 
 Exclusion Criteria 
 Other household member w/PAP use1-3 
 Other Criteria at Screening or Enrollment 
 1-wk Run-in with ≥ 3 hours/night average use3  
 Random Assignment 
 20-minute Acclimatize-to-PAP session1 
 PAP Initiation 
 Education about OSA and PAP provided by verbal, audio-visual and written 
methods13 
 Behavioral sleep medicine specialist provided pre-treatment information about 
PAP11* 
 Mask and humidification choice2 
 Exposure Intervals 
 PAP use criterion during auto-PAP titration period3 
 PAP FAQs for study staff to reduce risk of un-blinding participants (sham vs 
CPAP)1 
 Core Sleep Lab remote review of PAP use, leak data at regular defined 
intervals3 
 Core Sleep Lab provide corrective advice to sites, study team as needed3 
 Sleep hygiene advice specified by investigators as relevant to PAP adherence 
(alcohol and tobacco use, short sleep duration)11 
 Week 1 phone f/u1,3 
 Week 2 phone f/u11 
 Phone f/u based on PAP usage criterion1,3 
 Motivational and cognitive strategies used to increase PAP use11* 
Notes. †Exceptional defined as reported in ≤50% of included trials. *Not reported in 
published methodology or results; provided by corresponding author in response to 
electronic mail query requesting any additional protocol activities specific to PAP 
adherence. 
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Box 3.  Summary of PICO Questions and Evidence Density and Quality for Meta-
analyses of PAP Adherence Outcome in Patil, et al. 20194 
Q4:  In-lab vs. Ambulatory PAP titration based on 10 RCTs of high quality 
Q5:  Auto-titrating vs. continuous PAP based on 23 RCTs of moderate to high quality 
Q6:  Bi-level PAP or auto-Bi-level PAP vs. CPAP based on 4 RCTs of low quality 
Q7:  Modified pressure profile vs. no modified pressure profile based on 6 RCTs of low 
quality 
Q8:  Oral vs. nasal PAP mask based on 2 Cross-over RCTs and 1 RCT of low quality 
Q9:  PAP with humidity vs. no humidity based on 9 RCTs of low to moderate quality  
Q10: Educational intervention based on 7 RCTs of moderate quality or  
Behavioral intervention based on 6 RCTs of moderate-high quality  
vs. No intervention (interventions delivered prior to or during PAP) 
 Troubleshooting + education intervention based on 9 RCTs of moderate quality 
was separately meta-analyzed 
Q11: Tele-monitor guided intervention vs. no tele-monitoring based on 5 RCTs of high 
quality 
Notes. Abbreviations: PAP, Positive Airway Pressure; vs., versus; RCTs, Randomized 
Controlled Trials; CPAP, Continuous Positive Airway Pressure.  
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Box 4:  Publicly-reported Funding of Large-scale PAP Efficacy Trials (n=6) 
Trial Name  Funding Sources† Publicly 
Available Total 
Costs‡ 
APPLES NIH/NHLBI $14,094,332 
 
Spanish Cohort Trial Sociedad Española de Neumología y 
Cirugía Torácica 
 
Not Available 
MOSAIC British Heart Foundation 
Oxford Radcliffe Hospitals NHS Trust (UK) 
 
Not Available 
HeartBEAT NIH/NHLBI $3,679,973 
 
SAVE National Health and Medical Research 
Council (NHMRC) 
Philips Respironics (Industry) 
Respironics Foundation 
 
$8,904,248 
ISAACC ResMed (Industry) 
Fondo de Investigacion Sanitaria (Fondo 
Europeo de Desarrollo Regional)   
 
Not available 
†Funding source identified in methodology and/or result publication and/or in trial 
registry; ‡Data retrieved from funding agency database, when publicly-available. 
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Box 5.  Training Approaches for Site Staff in Large-scale PAP Trials: Leveraging 
Innovation in Delivery, Format and Style 
 Baseline Protocol Training 
 Face-to-Face Delivery 
 Didactic for general protocol information 
 Written materials to reinforce didactically delivered content 
 Diagrammatic materials for protocol scheme, decision-making 
 Teach-teach back for protocol delivery to participants 
 Role-play for protocol delivery to participants with peer-to-peer 
evaluation 
 Case-based learning with participant scenarios 
 Review of Manual of Operations (MOP) for PAP adherence protocol 
 Protocol Training Refreshers 
 Pocket Card Deck for PAP adherence protocols and procedures 
 Web-based portal with baseline training materials and access to refresher 
training materials 
 PAP adherence protocol and procedure checklists 
 Periodic Booster Training (PBT) and New Staff Training After Baseline Training 
(NST) 
 Web-based synchronous videoconferences: Challenging Scenarios, Case-
based Learning approach (PBT) 
 Web-based asynchronous Case-based learning (PBT) 
 Web-based or Nudge-based Push Notifications to web-based link: Brief 
training modules (≤ 5 minutes) (PBT) 
 Web-based synchronous and asynchronous training sessions (NST) 
 Peer-to-Peer training within sites with expert staff (NST) 
 Simulation training by remote access portal/tele-education (NST) 
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Supplemental Materials 
 
Where to Next for Optimizing Adherence in Large-scale Trials of PAP? 
Amy M. Sawyer, PhD, RN, Douglas M. Wallace, MD, Luis F. Buenaver, PhD,  
Alexa J. Watach, PhD, RN, Amy Blase, CCRA, Bruno Saconi, MS, RN,  
Sanjay R. Patel, MD, MS, Samuel T. Kuna, MD, Naresh M. Punjabi, MD, PhD  
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Supplement Table 1. Large-scale Trials Description of Methods Specific to Positive Airway Pressure Adherence by Study 
Period 
Trial Name 
(chronologic 
order by 
publication 
date) 
Screening 
Criteria† 
Or Other Pre-
Randomize 
Methods  
Random 
Assignment‡ 
PAP* Initiation Wk 1  Mo 1  > Mo 1  
Exposure 
APPLES1 Exclusion:  
Prior PAP 
use;  
Other house 
member 
w/PAP use 
(current or 
past)  
20-min PAP 
habituation 
exercise 
before 
titration PSG 
CPAP dispense 
by study 
personnel after 
titration PSG  
 
 
1-Wk: phone by 
RS X2 
 Ensure use 
 Manage 
problems 
 Protocol guide 
for PAP FAQs 
(reduce risk of 
un-blinding)** 
 
Contact 
w/<4hr/nt use 
Regular contact 
w/<4hr/nt use 
Regular contact 
w/<4hr/nt use 
 
4-Mo: FTFV w/study 
physician 
 PAP use discuss 
 
 
 
Spanish 
Cohort 
Trial71 
NR NR CPAP dispense 
at home after 
PSG or unattend 
HST at sleep 
center 
 5hr sleep 
 Leak criteria 
NR NR NR 
MOSAIC2 Exclusion: 
Prior PAP use 
NR PAP dispense 
by study staff 
after randomize 
 AutoPAP 
 Trained staff 
NR 3-Wk FTFV 
 PAP f/u 
2-Mo Phone 
 Advice 
 Supplies 
 
4-Mo Phone 
 Advice  
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 Humidity 
optional 
 Mask choice 
 Supplies 
 
PAP use data download 
minimum 1X b/w 
initiation-END 
 Residual AHI 
 Air Leaks 
 
HeartBEAT1
3 
Exclusion: 
Prior PAP use 
NR APAP dispense 
by site 
coordinator 
w/random assign 
 Auto-titrate 
X7days 
 Then set 
pressure  
 
Instruction by 
coordinator for 
use of assigned 
treatment 
 Humidity 
 Mask-fit by 
expert tech 
 
Healthy lifestyle 
& sleep 
education to 
both grps by 
slide 
presentation, 
hard-copy of 
slides, publicly 
available 
NR NR NR 
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education 
materials (AHA):  
 Regular sleep 
schedule 
 Avoid ETOH 
@bed 
 Sleep duration 
7-8hr/nt 
SAVE3 Exclusion:  
Neuro deficit 
prevent PAP 
mask apply;  
Prior PAP 
use;  
Other house 
member on 
PAP  
 
Other: 
1-wk Sham 
Run-In to 
exclude 
unlikely/ 
unwilling to 
adhere to 
PAP; patients 
informed of 
run-in 
purpose; 
sham device 
used; phone 
call Run-In 
Day 2-3; run-
in criterion 
Written 
information 
about PAP 
 
View DVD: 
Trial 
importance & 
adherence to 
PAP 
 
 
APAP dispense 
by study staff 
@FTFV 
 Best mask fit 
 Humidity 
 Auto-titrate X7 
days 
 Set pressure 
 Auto-titrate 
criteria: ≥3hr/nt 
average use, 
average leak 
<60L/min 
 If auto-titration 
criterion not 
met: 
 Address 
issues & 
repeat 
titration X7 
days  
1-Wk: Phone 
RS contact  
 Manage 
problems 
 
Additional phone 
contact if 
problems  
 
1-Mo: Remote 
review of PAP 
data by Core 
Sleep Lab 
 PAP use 
<3hr/nt 
 Air leak >60 
L/min 
 AHI>15/hr 
 
1-Mo: FTFV as 
needed for PAP 
problems 
 
Core Sleep Lab 
monitors PAP 
use, provide 
corrective 
advice to sites, 
study team   
3-Mo & 6-Mo: 
Remote review of PAP 
data by Core Sleep Lab 
 PAP use <3hr/nt 
 Air leak >60 
L/min 
 AHI>15/hr 
 
Q6-Mo: Phone 
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≥3hr/nt 
average 
ISAACC11 Exclusion: 
Prior PAP use 
NR In-hospital 
(enrolled 
inpatients) APAP 
by trained nurse 
followed by fixed 
pressure PAP 
 
Behavioral sleep 
medicine 
specialist 
provided pre-
treatment 
information; 
motivational and 
cognitive 
strategies to 
increase PAP 
use employed** 
 
 
15-Day: Phone   
 Resolve 
problems 
 Phone # 
provided to 
access study 
staff any time 
for PAP 
problems 
 FTFV schedule 
prn 
1-Mo: FTFV 
 Adapt to PAP 
support 
 Support PAP 
adhere using 
cognitive and 
motivational 
strategies** 
 Sleep hygiene 
advice by 
sleep unit staff 
at all 
scheduled 
visits; Health 
behavior 
advice include 
avoid evening 
ETOH, reduce 
tobacco, avoid 
short sleep  
3-Mo: FTFV 
 Adapt to PAP support 
 Support PAP adhere 
 
 
Notes. APPLES, Apnea Positive Pressure Long-term Efficacy Study; Spanish Cohort Trial; MOSAIC, Multicenter Obstructive Sleep 
Apnea Interventional Cardiovascular trial; HeartBEAT, Heart Biomarker Evaluation in Apnea Treatment; SAVE, Sleep Apnea 
Cardiovascular Endpoints study; ISAACC, Impact of Sleep Apnea syndrome in the evolution of Acute Coronary syndrome;  
 
†Inclusion and Exclusion Criteria that are specified for PAP adherence in methodology and/or result publication and/or 
supplemental/appendix materials and/or publicly-availably protocol materials. ‡Reported protocol activities specific to PAP 
use/initiation/adherence conducted concurrent with randomization; *PAP terminology used generically to represent all forms of 
positive airway pressure treatment. Where trials specified type of PAP, the specified type/mode is reported; **Additional 
information provided by corresponding author(s).  
 
Abbreviations – PAP, Positive Airway Pressure; CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway 
pressure; Wk, Week(s); Mo, Month(s); (E), Exclusion; NR, None Reported; w/, with; min, Minute(s); PSG, Polysomnogram; q, 
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every; FTFV, Face-to-Face Visit(s); prn, as needed; hr, hour(s); nt, night(s); RS, Research Staff; X, times; FAQs, Frequently Asked 
Questions; NA, Not Applicable; CV, cardiovascular; SD, secure digital; f/u, follow-up; AHI, apnea hypopnea index; DVD, digital 
versatile disk; @, at; L/min, liters per minute; #, number; ETOH, alcohol. 
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